In This Section      
 

Search Results

Title:
Radiation Immunodynamics: The Immune Response to Standard Therapy in Patients with Glioblastoma
Protocol Number:
J1840
Phase:
NULL
Physician:
Lawrence Kleinberg
Sites:
Johns Hopkins Kimmel Cancer Center in Baltimore
Purpose:
This study is assessing the immune system response during radiation therapy. The study involves measuring frequency of blood myeloid cells during radiotherapy/ temozolomide. The hypothesis of the study is : radiation increases immunosuppressive myeloid
Eligibility:
Inclusion 1. Greater than or equal to 18 years old2. Newly diagnosed glioblastoma, untreated except for surgery and corticosteroids2. Selected for standard radiotherapy (5940-6000 cGy) and temozolomide (75 mg/m2/day)We will also recruit up to an additional 10 patients receiving non-standard radiation fractionation schemes for immunologic comparison.Exclusion 1. Recurrent GBM
Treatment:
22 patients will be recruited with pathologically confirmed new GBM. Radiation will be given for 5 days a week. Donor Blood will be collected at seven time points: ±7 days of RT simulation prior to start of RT, every 7±3 fractions throughout the duration of RT, within 7 days of the last fraction of RT and one month after RT ±7 days. . Donor blood will be processed immediately following collection of each biosample at The Bloomberg~Kimmel Institute for Cancer Immunotherapy at JHH.
Population:
Adult
Last Update
03/05/2019 05:03 AM